Neurocrine Announces Phase I Clinical Trial Results with Its Proprietary CRF1 Receptor Antagonist Compound for Depression and Anxiety
(PR Newswire)...CRF functions as a neurotransmitter in the brain and plays a critical role in coordinating the body`s response to stress.......immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes....- Mar 08 7:30 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010308/lath050.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines